---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-002799"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:37:24.481804+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anika Q1 revenue up 13% to $29.6M; adjusted EBITDA improves to $4.3M; directors resign

## Summary
- Total revenue $29.6M (+13% YoY); Commercial Channel +12%, OEM +14%.
- Gross margin 64.2% vs 56.1% YoY on operational execution and favorable mix.
- GAAP loss from continuing ops $5.1M ($0.37 diluted); adjusted net income $3.8M ($0.27 diluted).
- Adjusted EBITDA $4.3M vs $0.1M prior year; FY2026 guidance reaffirmed (revenue $114-122.5M).
- Board members Jellison and Larsen resign effective 2026 annual meeting; share repurchase $15M completed at avg $10.76/share.

## SEC filing metadata
- accession: 0001171843-26-002799
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/f8k_042926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-002799
- JSON: https://secwatch.observer/filing/0001171843-26-002799.json
- Plain text: https://secwatch.observer/filing/0001171843-26-002799.txt

## Key facts
- Earnings Releases
  Anika Therapeutics, Inc. reported first quarter 2026 results: revenue $29.6 million, net income $5.1 million loss, EPS ($0.37) per diluted share.
  - Period: first quarter 2026
  - Revenue: $29.6 million
  - Net income: $5.1 million loss
  - EPS: ($0.37) per diluted share
  - Result: reported results
  source text: First Quarter 2026 Continuing Operations Financial Summary Revenue $29.6 million, up 13% year over year Commercial Channel revenue $12.6 million, up 12% OEM Channel revenue $17.0 million, up 14% Gross margin 64.2% Operating expenses $24.5 million, including $4.9 million of one-time severance expenses GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm
- Earnings Releases
  Anika Therapeutics, Inc. reported fiscal year 2026 results: revenue $114 to $122.5 million. Guidance reaffirmed.
  - Period: fiscal year 2026
  - Revenue: $114 to $122.5 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Fiscal 2026 Guidance Anika is maintaining the previously provided 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year Commercial Channel, $53 to $58 million, representing growth of 10% to 20% year over year OEM Channel, $61 to $64.5 million, flat to modestly lower year over year Adjusted EBITDA as a percent of revenue between 5% and 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm
- Executive change
  William R. Jellison resigned as Class I member of the Board of Directors at Anika Therapeutics, Inc..
  - Action: resigned
  - Role: Class I member of the Board of Directors
  source text: On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm
- Executive change
  Glenn R. Larsen resigned as Class II member of the Board at Anika Therapeutics, Inc..
  - Action: resigned
  - Role: Class II member of the Board
  source text: On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.